Anand Patel, CMO, of Conquest Research and a Principal Investigator Shares Insights from the Significant Benefits of LX9211
PharmaShots
JUNE 19, 2023
about the LX9211 for the treatment of Diabetic Peripheral Neuropathic Pain. Anand Patel: LX9211 is a novel oral medication currently under development by Lexicon Pharmaceuticals for the treatment of multiple chronic neuropathic pain states. Smriti: Please elaborate on the details (MOA, ROA, formulation, etc.)
40 
Let's personalize your content